Technology Brief -- Genentech Inc.:
   First European Unit Is Set
   As Part of Roche Accord
Genentech said it hopes to seek clearance in Europe to
market DNase for cystic fibrosis in early 1993. It said the
agreement with Roche will last ten years from the time each
country first approves the treatment.